U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06828796) titled 'Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation with Post-Transplant Cyclophosphamide' on Feb. 06.
Brief Summary: To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Hematologic Disease and Disorders
Hematopoietic Cell Transplant
Intervention:
DRUG: Tacrolimus
Begins Day -1 and continues to Day +90 or Day +180 after transplant
DRUG: Cyclophosphamide
Given Days +3 and +4 after tr...